CBUS vs. LFVN, MBII, NAII, AVD, LXFR, ARQ, SLI, ORGN, EVGN, and VGAS
Should you be buying Cibus stock or one of its competitors? The main competitors of Cibus include LifeVantage (LFVN), Marrone Bio Innovations (MBII), Natural Alternatives International (NAII), American Vanguard (AVD), Luxfer (LXFR), ARQ (ARQ), Standard Lithium (SLI), Origin Materials (ORGN), Evogene (EVGN), and Verde Clean Fuels (VGAS).
LifeVantage (NASDAQ:LFVN) and Cibus (NASDAQ:CBUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
35.3% of LifeVantage shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 6.8% of LifeVantage shares are held by insiders. Comparatively, 49.4% of Cibus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Cibus has a consensus price target of $23.67, suggesting a potential upside of 431.84%. Given Cibus' higher probable upside, analysts plainly believe Cibus is more favorable than LifeVantage.
In the previous week, LifeVantage had 3 more articles in the media than Cibus. MarketBeat recorded 5 mentions for LifeVantage and 2 mentions for Cibus. Cibus' average media sentiment score of 0.64 beat LifeVantage's score of 0.32 indicating that Cibus is being referred to more favorably in the news media.
LifeVantage has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
LifeVantage has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Cibus has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.
LifeVantage has a net margin of 1.47% compared to Cibus' net margin of -9,856.84%. LifeVantage's return on equity of 27.85% beat Cibus' return on equity.
LifeVantage received 214 more outperform votes than Cibus when rated by MarketBeat users. However, 100.00% of users gave Cibus an outperform vote while only 77.82% of users gave LifeVantage an outperform vote.
Summary
LifeVantage beats Cibus on 10 of the 18 factors compared between the two stocks.
Get Cibus News Delivered to You Automatically
Sign up to receive the latest news and ratings for CBUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CBUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
